Research Paper Volume 14, Issue 18 pp 7568—7586
Novel TRKB agonists activate TRKB and downstream ERK and AKT signaling to protect Aβ-GFP SH-SY5Y cells against Aβ toxicity
Figure 7. Comparison of BDNF’s and LMDS compound’s signaling activation. (A) Assessment of ROS in Aβ-GFP cells uninduced, untreated, treated with treated with BDNF at 1–100 ng/ml, or LMDS-1, -2 at 1.2–5 μM (n = 3). The relative ROS of uninduced cells (Dox-) was normalized (100%). Shown below are images of CellROX® Deep Red stain (red). (B) Assessment of p-ERK (T202/Y204), ERK, p-AKT (S473), AKT, p-CREB (S133) and CREB levels with LMDS-1, -2 (5 μM) or BDNF (100 ng/ml) treatment by immunoblot using GAPDH as a loading control (n = 3). To normalize, protein expression level in untreated cells was set at 100%. P values: comparisons between induced vs. uninduced cells (#P < 0.05, ##P < 0.01), or compound-treated vs. untreated cells (*P < 0.05, **P < 0.01, ***P < 0.001). (one-way ANOVA with a post hoc Tukey test).